Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Riociguat - Bayer

Next Previous
Drug Profile

Riociguat - Bayer

Alternative Names: Adempas; BAY-32521; BAY-63-2521

Latest Information Update: 07 Oct 2025

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Bayer
  • Class 2 ring heterocyclic compounds; Antifibrotics; Carbamates; Diamines; Fluorobenzenes; Pyrazoles; Pyridines; Pyrimidines; Skin disorder therapies; Small molecules; Vascular disorder therapies
  • Mechanism of Action Guanylate cyclase stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Systemic scleroderma; Pulmonary hypertension; Pulmonary arterial hypertension
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Pulmonary arterial hypertension; Pulmonary hypertension
  • Phase II Cystic fibrosis; Systemic scleroderma
  • No development reported Raynaud's disease

Most Recent Events

  • 23 Jul 2025 Bayer completes the phase II LEPHT trial for Pulmonary hypertension associated with Left ventricular systolic dysfunction in USA, Australia, Austria, Belgium, Canada, China, Czech Republic, Denmark, France, Germany, Italy, Japan, Netherlands, Poland, Singapore, Spain, Switzerland and United Kingdom (NCT01065454)
  • 03 Jul 2025 Bayer completes a phase II trial in Pulmonary arterial hypertension in Germany (PO) (NCT00694850)
  • 22 Feb 2023 No development reported - Phase-III for Pulmonary hypertension in Sweden, Greece, Ireland, Netherlands, United Kingdom, Spain, Slovakia, Portugal, Poland, Italy, Germany, Denmark, Czech Republic, Belgium, Austria, Thailand (PO) (Bayer pipeline, February 2023)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top